Posted by Sigolene on October 18, 2000, at 4:49:16
In reply to Re: Reboxetine + Ritalin ?? IMAO + Ritalin ?? » Sigolene, posted by SLS on October 17, 2000, at 21:36:46
We have toloxatone and iproniazide.
I know nothing about these two meds.
> > Any experience with these combinations ?
> >
> > IMAO (especially moclobemide) + Ritalin ???
> >
> > Reboxetine + Ritalin ???
> >
> > Tanks Sigolène
>
>
> Which other IMAOs are currently available?
>
> toloxatone?
> brofaromine?
> befloxetone?
>
> Moclobemide, although a miracle drug for some (aren't they all?), is notorious for "pooping-out" very quickly. Usually, someone will begin to feel better in one or two weeks. However, more often than not, the dosage must be raised higher and higher to maintain an antidepressant response. The effective range for moclobemide is between 600mg - 900mg, and sometimes as high as 1200mg. I can think of no reason why it could not be combined with reboxetine or ritalin. However, I would still recommend against adding an SSRI to moclobemide, although there are two well-known Canadian doctors who do so (Joffe and Bakish) in treatment-resistant cases.
>
> What do you know about toloxatone?
>
> Thanks, Sigolène
>
>
> - Scott
>
>
> ---------------------------------------------------------
>
> J Clin Psychiatry 1994 Jan;55(1):24-5 Related Articles, Books, LinkOut
>
>
> Combined SSRI-moclobemide treatment of psychiatric illness.
>
> Joffe RT, Bakish D
>
> Mood Disorders Program, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.
>
> BACKGROUND: To determine the efficacy and safety of a serotonin selective reuptake inhibitor (SSRI) combined with moclobemide in the treatment of 11 patients with various DSM-III-R diagnoses. METHOD: Subjects received moclobemide in doses of 150 to 800 mg/day together with sertraline (N = 5) in doses of 25 to 200 mg/day or fluvoxamine (N = 6) in doses of 50 to 200 mg/day. Patients were carefully monitored for side effects and for clinical response at the end of the trial, which lasted a minimum of 5 weeks. RESULTS: The combination was tolerated extremely well. Insomnia was the most common side effect, occurring in 5 of 11 subjects. A marked or complete therapeutic response was noted in 8 of 11 subjects. CONCLUSION: This open clinical trial suggests that combined SSRI-moclobemide treatment appears to be safe and well tolerated. It may also have therapeutic effects in treatment-refractory patients.
>
> Publication Types:
> Clinical trial
> Controlled clinical trial
>
> PMID: 8294388, UI: 94124472
poster:Sigolene
thread:46550
URL: http://www.dr-bob.org/babble/20001012/msgs/46649.html